News
CDTX
21.74
-1.98%
-0.44
Weekly Report: what happened at CDTX last week (0113-0117)?
Weekly Report · 2d ago
Weekly Report: what happened at CDTX last week (0106-0110)?
Weekly Report · 01/13 10:22
Cidara Therapeutics Announces Leadership Changes and Appointments
TipRanks · 01/07 22:30
Weekly Report: what happened at CDTX last week (1230-0103)?
Weekly Report · 01/06 10:27
Biotech Alert: Searches spiking for these stocks today
TipRanks · 01/03 18:30
Biotech Alert: Searches spiking for these stocks today
TipRanks · 01/02 16:15
Weekly Report: what happened at CDTX last week (1223-1227)?
Weekly Report · 12/30/2024 10:23
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders
Seeking Alpha · 12/23/2024 21:56
Cidara Therapeutics files to sell 7.04M shares of common stock for holders
TipRanks · 12/23/2024 21:45
Twelve option delistings on December 23rd
TipRanks · 12/23/2024 13:35
Weekly Report: what happened at CDTX last week (1216-1220)?
Weekly Report · 12/23/2024 10:27
Weekly Report: what happened at CDTX last week (1209-1213)?
Weekly Report · 12/16/2024 10:28
Cidara Therapeutics Price Target Announced at $34.00/Share by RBC Capital
Dow Jones · 12/13/2024 14:36
RBC Capital Initiates Coverage On Cidara Therapeutics with Outperform Rating, Announces Price Target of $34
Benzinga · 12/13/2024 14:26
Cidara Therapeutics initiated with an Outperform at RBC Capital
TipRanks · 12/13/2024 11:15
Weekly Report: what happened at CDTX last week (1202-1206)?
Weekly Report · 12/09/2024 10:26
Innovative Influenza Prevention and Strategic Moves Elevate Cidara Therapeutics’ Stock Potential
TipRanks · 12/05/2024 17:48
Cidara Therapeutics Is Maintained at Strong Buy by WBB Securities
Dow Jones · 12/05/2024 15:12
Cidara Therapeutics Price Target Raised to $45.00/Share From $40.00 by WBB Securities
Dow Jones · 12/05/2024 15:12
WBB Securities Maintains Strong Buy on Cidara Therapeutics, Raises Price Target to $45
Benzinga · 12/05/2024 15:02
More
Webull provides a variety of real-time CDTX stock news. You can receive the latest news about Cidara Theraptcs through multiple platforms. This information may help you make smarter investment decisions.
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.